<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001451</url>
  </required_header>
  <id_info>
    <org_study_id>GDX012U-001</org_study_id>
    <nct_id>NCT05001451</nct_id>
  </id_info>
  <brief_title>Study of GDX012 in Patients With MRD Positive AML</brief_title>
  <official_title>A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GammaDelta Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GammaDelta Therapeutics Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic&#xD;
      activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by&#xD;
      multiparametric flow cytometry.&#xD;
&#xD;
      The study will consist of a dose escalation stage to evaluate various doses of GDX012 after a&#xD;
      lymphodepletion regimen comprising fludarabine and cyclophosphamide. Following determination&#xD;
      of the MTD of GDX012, the study will expand at the MTD. Patients will be followed up for 12&#xD;
      months, after receiving GDX012.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 100 days</time_frame>
    <description>AEs and SAEs occurring following administration of GDX012</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent clinically significant abnormal laboratory assessments</measure>
    <time_frame>Up to 100 days</time_frame>
    <description>Standard clinical laboratory assessments for organ function (i.e. heart, kidney, liver)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 100 days</time_frame>
    <description>DLTs occurring following administration of GDX012, measured using CTCAE 5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish the maximum tolerated dose (MTD) of GDX012</measure>
    <time_frame>Up to 100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the antileukemic activity of GDX012</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Minimal residual disease (MRD) assessed by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the antileukemic activity of GDX012</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Incidence of patients converting from MRD positive to MRD negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the antileukemic activity of GDX012</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Progression-free survival (PFS) and overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>GDX012 Suspension for IV Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GDX012 Suspension for IV Infusion</intervention_name>
    <description>Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.&#xD;
Drug: Fludarabine; chemotherapy for lymphodepletion&#xD;
Drug: Cyclophosphamide; chemotherapy for lymphodepletion</description>
    <arm_group_label>GDX012 Suspension for IV Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Weight ≥ 40 kg&#xD;
&#xD;
          -  Anticipated life expectancy &gt; 3 months prior to lymphodepletion&#xD;
&#xD;
          -  Karnofsky Performance Score ≥ 70%&#xD;
&#xD;
          -  Histologically confirmed diagnosis of AML&#xD;
&#xD;
          -  In complete response (CR) (including CRi/CRp); patients in first, second or subsequent&#xD;
             CR (including CRi/CRp) are permitted&#xD;
&#xD;
          -  MRD detected in bone marrow by MFC&#xD;
&#xD;
          -  Negative pregnancy test (females of childbearing potential only)&#xD;
&#xD;
          -  Agree to use effective birth control&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50%&#xD;
&#xD;
          -  Platelet Count ≥ 20 x 109/L&#xD;
&#xD;
          -  Prothrombin Time or INR ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation)&#xD;
&#xD;
          -  Partial Thromboplastin Time ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Creatinine Clearance ≥ 40mL/min&#xD;
&#xD;
          -  Serum Total Bilirubin ≤ 1.5 x ULN (unless documented Gilbert's Syndrome with Direct&#xD;
             Bilirubin &lt; 35% of Total Bilirubin)&#xD;
&#xD;
          -  ALT ≤ 2.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cytotoxic chemotherapy within 3 weeks&#xD;
&#xD;
          -  Immune therapy within 4 weeks&#xD;
&#xD;
          -  Immunosuppressive therapy within 2 weeks (with exceptions)&#xD;
&#xD;
          -  Investigational treatment or interventional clinical trial within 4 weeks or 5&#xD;
             half-lives (if known), whichever is longer&#xD;
&#xD;
          -  Major surgery within 4 weeks and/or not fully recovered from surgery-related&#xD;
             toxicities&#xD;
&#xD;
          -  Known hypersensitivity to chemotherapy, other agents, or excipients used in this study&#xD;
&#xD;
          -  Female patient that is pregnant or lactating/breastfeeding&#xD;
&#xD;
          -  Ongoing toxicity from prior anti-cancer therapy that have not recovered to ≤ Grade 1&#xD;
             (with exceptions)&#xD;
&#xD;
          -  History of chronic or recurrent autoimmune or immune-mediated disease requiring&#xD;
             steroids or other immunosuppressive treatments (including anti-tumor necrosis factor&#xD;
             agents)&#xD;
&#xD;
          -  Active CNS involvement (i.e. leukemic infiltration)&#xD;
&#xD;
          -  Any other malignancy that requires active therapy&#xD;
&#xD;
          -  Uncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months)&#xD;
&#xD;
          -  Active infection with HIV, Hepatitis B or Hepatitis C&#xD;
&#xD;
        NOTE: other protocol defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Koslowski, MD</last_name>
    <role>Study Director</role>
    <affiliation>GammaDelta Therapeutics Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monzr M Al Malki, MD</last_name>
      <phone>833-310-2278</phone>
      <email>malmalki@coh.org</email>
    </contact>
    <investigator>
      <last_name>Monzr M Al Malki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Marin, MD</last_name>
      <phone>713-792-4179</phone>
      <email>dmarin@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Marin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MRD</keyword>
  <keyword>gamma delta T-cells</keyword>
  <keyword>allogeneic</keyword>
  <keyword>cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

